MX2024001328A - Nuevas moleculas multiespecificas. - Google Patents

Nuevas moleculas multiespecificas.

Info

Publication number
MX2024001328A
MX2024001328A MX2024001328A MX2024001328A MX2024001328A MX 2024001328 A MX2024001328 A MX 2024001328A MX 2024001328 A MX2024001328 A MX 2024001328A MX 2024001328 A MX2024001328 A MX 2024001328A MX 2024001328 A MX2024001328 A MX 2024001328A
Authority
MX
Mexico
Prior art keywords
novel multi
specific molecules
sipralpha
present disclosure
pharmaceutical compositions
Prior art date
Application number
MX2024001328A
Other languages
English (en)
Spanish (es)
Inventor
Jing Wang
Zhihao Wu
Rui Gao
Hongtao Lu
Dawei Sun
Yanan Geng
Haixia Jiang
Xiaofeng Niu
Yangsheng Qiu
Original Assignee
Elpiscience Suzhou Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elpiscience Suzhou Biopharma Ltd filed Critical Elpiscience Suzhou Biopharma Ltd
Publication of MX2024001328A publication Critical patent/MX2024001328A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
MX2024001328A 2021-07-28 2022-07-28 Nuevas moleculas multiespecificas. MX2024001328A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2021109028 2021-07-28
CN2022103725 2022-07-04
PCT/US2022/074284 WO2023010098A2 (en) 2021-07-28 2022-07-28 Novel multi-specific molecules

Publications (1)

Publication Number Publication Date
MX2024001328A true MX2024001328A (es) 2024-04-01

Family

ID=85088266

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024001328A MX2024001328A (es) 2021-07-28 2022-07-28 Nuevas moleculas multiespecificas.

Country Status (10)

Country Link
US (1) US20240336686A1 (cg-RX-API-DMAC7.html)
EP (1) EP4377357A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024527043A (cg-RX-API-DMAC7.html)
KR (1) KR20240039005A (cg-RX-API-DMAC7.html)
CN (1) CN118055946A (cg-RX-API-DMAC7.html)
AU (1) AU2022319934A1 (cg-RX-API-DMAC7.html)
CA (1) CA3226306A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024001328A (cg-RX-API-DMAC7.html)
TW (1) TW202311296A (cg-RX-API-DMAC7.html)
WO (1) WO2023010098A2 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022063272A1 (en) * 2020-09-28 2022-03-31 Elpiscience (Suzhou) Biopharma, Ltd. Novel anti-claudin18 antibodies
WO2024153193A1 (en) * 2023-01-18 2024-07-25 Elpiscience (Suzhou) Biopharma, Ltd. Bi-specific molecules targeting sirpa and claudin 18.2

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015138600A2 (en) * 2014-03-11 2015-09-17 The Board Of Trustees Of The Leland Stanford Junior University Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies
EP3634484A4 (en) * 2017-06-05 2022-01-12 The Council of the Queensland Institute of Medical Research A COMBINATION OF OR A BI-SPECIFIC BINDING MOLECULE TO AN IMMUNOCONTROL MOLECULE ANTAGONIST AND A RANK-L (NF-κB-LIGAND) ANTAGONIST FOR CANCER THERAPY OR PROPHYLAXIS AND USES THEREOF
WO2019183266A1 (en) * 2018-03-21 2019-09-26 ALX Oncology Inc. Antibodies against signal-regulatory protein alpha and methods of use
MX2020013068A (es) * 2018-07-10 2021-03-02 Univ Kobe Nat Univ Corp Anticuerpo anti proteína reguladora de señales alfa sirpalfana.
WO2021003082A1 (en) * 2019-07-03 2021-01-07 Phanes Therapeutics, Inc. Anti-claudin 18.2/anti-cd47 bispecific antibodies and uses thereof
US20210347908A1 (en) * 2019-08-20 2021-11-11 Elpiscience (Suzhou) Biopharma, Ltd. Novel anti-sirpa antibodies
EP4081548A4 (en) * 2019-12-24 2024-07-24 LaNova Medicines Limited Anti-sirp? monoclonal antibodies and uses thereof

Also Published As

Publication number Publication date
WO2023010098A2 (en) 2023-02-02
CA3226306A1 (en) 2023-02-02
TW202311296A (zh) 2023-03-16
WO2023010098A3 (en) 2023-04-27
US20240336686A1 (en) 2024-10-10
JP2024527043A (ja) 2024-07-19
CN118055946A (zh) 2024-05-17
AU2022319934A1 (en) 2024-03-07
KR20240039005A (ko) 2024-03-26
EP4377357A2 (en) 2024-06-05
EP4377357A4 (en) 2026-05-06

Similar Documents

Publication Publication Date Title
ECSP19026178A (es) Anticuerpos anti-pd-1 y sus usos
BR112022006977A2 (pt) Aminas bicíclicas como inibidores de cdk2
ECSP19050049A (es) Anticuerpos anti-ox40 y sus usos
AR120883A1 (es) Anticuerpos anti-fgfr2b
CL2021001179A1 (es) Anticuerpos específicos para tl1a y ácidos nucleicos que los codifican (divisional de la solicitud no. 201801596).
CL2021000717A1 (es) Constructos de anticuerpo para cd70 y cd3. divisional de solicitud 270-2018
CO2022001453A2 (es) Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2
MX2022002111A (es) Novedosos anticuerpos anti-cldn18.2.
CY1123932T1 (el) Δομες πολυειδικου αντισωματος
MX2021009259A (es) Conjugados de il-2 y metodos de uso del mismo.
AR120886A1 (es) Anticuerpos anti-fgfr2b
MX2017003359A (es) Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.
CL2020000937A1 (es) Anticuerpo multiespecífico.
BR112019005305A2 (pt) compostos espirocíclicos
CR20180162A (es) Moléculas biespecíficas de unión a antígeno activadoras de células t
MX2021004925A (es) Variantes de adn-polimerasa modificadas.
CR20190150A (es) Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad, kits, y métodos
CR20180605A (es) Anticuerpos anti-cd40 y sus usos
CO2023011463A2 (es) Nuevos anticuerpos anti-cd24
CO2018008304A2 (es) Compuestos antiproliferativos y sus composiciones farmacéuticas y usos
AR120884A1 (es) Anticuerpos anti-fgfr2b
CO2023015915A2 (es) Anticuerpos anti-ccr8
MX2018003592A (es) Sales y formas solidas de un antibiotico de monobactam.
MX2024010955A (es) Nuevos anticuerpos anti-cd3 y usos de los mismos
BR112019003712A2 (pt) composições marcadoras, e métodos para produção e uso das mesmas